Exploring US High Growth Tech Stocks for Potential Expansion
Uncategorized
Exploring US High Growth Tech Stocks for Potential Expansion
07 mins
As the U.S. stock market reaches new highs with the S&P 500 closing at a record level and tech stocks leading recent gains, investors are closely watching high-growth sectors for potential opportunities. In this environment, identifying strong tech stocks involves considering their capacity for innovation and resilience amid evolving economic conditions.
Let’s dive into some prime choices out of from the screener.
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Viant Technology Inc. is an advertising technology company with a market capitalization of approximately $741.88 million.
Operations: Viant Technology generates revenue primarily through its Enterprise Technology Platform, which contributed $324.13 million. The company focuses on providing advertising technology solutions to its clients.
Viant Technology’s strategic moves, including a notable integration with iHeartMedia and partnerships like the one with Molson Coors, underscore its commitment to enhancing programmatic advertising and outcome-driven strategies. This is evident from its 13.3% annual revenue growth and robust earnings growth of 44.2% per year, outpacing the US market average. The company’s recent third-quarter sales increase to $85.58 million from $79.92 million the previous year reflects a solid execution of its business model in a competitive tech landscape. Viant’s focus on direct publisher relationships through initiatives like Direct Access further positions it as an innovator in connected TV (CTV) and digital advertising spaces, leveraging advanced technology to optimize ad spending efficiency and effectiveness.
DSP Revenue and Expenses Breakdown as at Dec 2025
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Dynavax Technologies Corporation is a commercial-stage biopharmaceutical company that specializes in developing and commercializing vaccines both in the United States and internationally, with a market cap of approximately $1.31 billion.
Operations: Dynavax Technologies focuses on the discovery, development, and commercialization of novel vaccines, generating revenue of $330.51 million. The company operates in the biopharmaceutical sector with a primary emphasis on vaccine innovation and distribution both domestically and internationally.
Dynavax Technologies, amid a transformative phase, has shown robust financial and operational growth with its recent acquisition by Sanofi for $1.9 billion, signaling strong market confidence. This strategic move is complemented by a significant 52.76% forecast in annual earnings growth and an impressive jump in quarterly revenue from $80.63 million to $94.88 million year-over-year. The firm’s commitment to innovation is evident from its R&D initiatives like the Z-1018 shingles vaccine, which competes closely with established products, showcasing Dynavax’s potential to impact public health significantly.
DVAX Revenue and Expenses Breakdown as at Dec 2025
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Phreesia, Inc. offers an integrated SaaS-based software and payment platform tailored for the healthcare industry across the United States and Canada, with a market cap of approximately $992.93 million.
Operations: Phreesia generates revenue primarily from its Technology Solutions segment, which accounted for $463.21 million.
Phreesia has demonstrated a notable turnaround, transitioning from a net loss of $14.4 million to a net income of $4.27 million in its recent quarterly report, reflecting significant operational improvements and effective cost management. This shift is underscored by an impressive 10.7% annual revenue growth, positioning the company well within the competitive tech landscape. Further bolstering investor confidence, Phreesia has raised its fiscal 2026 revenue forecast to between $479 million and $481 million, indicative of sustained growth momentum and strategic business expansions such as the AccessOne integration expected to contribute an additional $7.5 million in revenue. This proactive approach in forecasting and adapting to market demands suggests promising prospects for Phreesia’s continued expansion in high-tech solutions.
PHR Revenue and Expenses Breakdown as at Dec 2025
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include DSPDVAX and PHR.
